Kantonsspital St. Gallen / Department of Neurosurgery
Sankt Gallen, Canton of St. Gallen, 9000, Switzerland
NCT Number: NCT03977961
The study determines the reliability and validity of the 6-Minute Walking Test (6MWT) in patients with lumbar degenerative disc disease (DDD).
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Sankt Gallen, Canton of St. Gallen, 9000, Switzerland
The purposes of the study is to assess the ability of the 6-Minute Walking Test (6MWT) as a reliable and standardized objective outcome assessment and its relation to already established subjective patient reported outcome measures in patients suffering from lumbar degenerative disc disease. We want to use an existing smartphone-application that uses global positioning system (GPS) coordinates to measure walking distance. Applying self- measurement of the 6MWT before and after a therapeutic intervention, we determine objective functional impairment (OFI) in patients. The results of this study add to the understanding of achievable objective outcomes after therapeutic interventions applied to patients with DDD and examines patients acceptance for smartphone based self-measurement.
Primary Objectives The primary objective is to determine the reliability and validity of the 6-Minute Walking Test (6MWT) in patients with lumbar degenerative disc disease (DDD)
Secondary objectives are
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 4-12 weeks
Raw walking distance (in m), as measured with the 6MWT, between the baseline- (before surgery) and follow-up assessment
Time frame: 4-12 weeks
Difference in Time to First Symptoms (TTFS; in sec) as measured by the 6MWT, between the baseline- and follow-up assessment
Time frame: 4-12 weeks
Difference in Distance to First Symptoms (DTFS, in m), as measured by the 6MWT, between the baseline- and follow-up assessment
Time frame: 4-12 weeks
Difference in PROM, as measured by the Zurich Claudication Questionnaire (ZCQ average score, range 0 (best) - 4,5 (worst), between the baseline- and follow-up assessment.
Time frame: 4-12 weeks
Difference in health-related quality of life (hrQoL), as measured by the Core Outcome Measures Index (COMI average score, range 0 (best) - 10 (worst)), between the baseline- and follow-up assessment
Time frame: 4-12 weeks
Correlation of TTFS/DTFS in the 6MWT with the ZCQ score at baseline
Time frame: 4-12 weeks
Correlation of TTFS in the 6MWT with the ZCQ score at follow-up
Time frame: 4-12 weeks
Correlation of TTFS/DTFS in the 6MWT with the COMI score at baseline
Time frame: 4-12 weeks
Correlation of TTFS/DTFS in the 6MWT with the COMI score at follow-up
Time frame: 4-12 weeks
Correlation of TTFS/DTFS in the 6MWT with the Timed up go Test (TUG) at baseline
Time frame: 4-12 weeks
Correlation of TTFS/DTFS in the 6MWT with the TUG at follow-up
Time frame: 6 weeks to 1 day before surgery as well as 4-12 weeks after surgery
Test-retest reliability of the 6MWT in patients with lumbar degenerate disc disease, tested two consecutive times with the 6MWT App (within 3 days) before as well as after surgery.
Cantonal Hospital of St. Gallen
Other
Acronym: 6MWT-DDD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04062942
Bone Diseases, Intervertebral disc disease
Sankt Gallen, Switzerland
View Trial DetailsNCT03733626
Bone Diseases, Degenerative Disc Disease
Royal Oak, Michigan, United States
View Trial DetailsNCT05345249
Bone Diseases, Fusion of Spine
Ubbergen, Gelderland, Netherlands
View Trial DetailsNCT04587401
Bone Diseases, Cardiovascular Diseases
Antalya, Turkey (Türkiye)
View Trial Details